D.A. Davidson & CO. Increases Stake in BioLife Solutions, Inc. (NASDAQ:BLFS)

D.A. Davidson & CO. raised its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 1.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 41,179 shares of the medical equipment provider’s stock after acquiring an additional 519 shares during the quarter. D.A. Davidson & CO. owned approximately 0.09% of BioLife Solutions worth $1,069,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Stifel Financial Corp increased its stake in shares of BioLife Solutions by 5.4% in the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after purchasing an additional 670 shares in the last quarter. Mark Sheptoff Financial Planning LLC purchased a new position in BioLife Solutions during the third quarter worth approximately $28,000. Curi RMB Capital LLC grew its holdings in BioLife Solutions by 0.5% in the third quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock valued at $10,565,000 after purchasing an additional 2,283 shares during the period. Quest Partners LLC purchased a new stake in shares of BioLife Solutions in the third quarter valued at approximately $57,000. Finally, Cerity Partners LLC raised its stake in shares of BioLife Solutions by 6.6% during the 3rd quarter. Cerity Partners LLC now owns 44,914 shares of the medical equipment provider’s stock worth $1,125,000 after buying an additional 2,776 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

BioLife Solutions Stock Down 3.1 %

Shares of NASDAQ BLFS opened at $26.67 on Monday. The stock has a market cap of $1.24 billion, a PE ratio of -25.16 and a beta of 1.91. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12-month low of $14.50 and a 12-month high of $29.55. The company has a 50-day moving average of $26.93 and a 200 day moving average of $25.51.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, CFO Troy Wichterman sold 987 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74. Following the transaction, the chief financial officer now owns 121,779 shares of the company’s stock, valued at approximately $3,290,468.58. The trade was a 0.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Aby J. Mathew sold 7,604 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the sale, the executive vice president now owns 276,315 shares of the company’s stock, valued at approximately $7,551,688.95. The trade was a 2.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,678 shares of company stock worth $317,990 in the last ninety days. Insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. TD Cowen lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright dropped their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Northland Securities boosted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. KeyCorp raised their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Finally, Benchmark reiterated a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, BioLife Solutions presently has an average rating of “Moderate Buy” and an average target price of $29.43.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.